Rational design of #MGDs going way beyond g-loops. $glue

PPI prediction is moving at breakneck speed! At Monte Rosa Therapeutics, Inc , we’re pushing past nature’s playbook to chart new frontiers in drug discovery— integrating our cutting-edge PPI tools in the Queen Discovery Engine to degrade targets once thought undruggable.

Pleased to announce FDA clearance of our IND application for MRT-8102, a NEK7-directed molecular glue degrader designed to target inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/4l0ky8C

Today, we published new discoveries in a Science Magazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine: bit.ly/4eBn8Q

Over the last 6 years we Monte Rosa Therapeutics, Inc have pushed the limits on molecular glue degrader design. The term MGD didn’t even exist 6 years ago! Very proud of the team and exited about what the technology holds! Go QuEEN! Aye-Oh!

Congratulations to the Monte Rosa Therapeutics, Inc team for having their work featured on the cover of Science Magazine! We (DIMENSION) are tremendously excited about the future of molecular glue degraders (MGDs) and induced proximity writ large. Even in 2025, we've only scratched the

Dimension portco Monte Rosa Therapeutics, Inc casually on the cover of Science 🚀

Cool paper from Monte Rosa on Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition | Science science.org/doi/10.1126/sc…

More proteins may be druggable with molecular glue degraders than initially thought, according to a new paper in Science from the biotech firm Monte Rosa Therapeutics. cen.acs.org/pharmaceutical…

ICYMI: Last week, we published discoveries in a Science Magazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs & our QuEEN™ discovery engine. bit.ly/4kvoGwH

Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine.

We’ve shown the molecular glue target space is broader than previously understood and we believe we're uniquely positioned to harness its potential: bit.ly/4koxZ1m

40yrs LiveAid! 40 years ago at 6.41pm Queen came on stage for their legendary performance! When we had to name our Monte Rosa Therapeutics, Inc product engine we wanted it to represent greatness and doing the impossible. So we picked QuEEN! Best choice ever! Aye-Oh!

We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/4m5JOe7

𝐂𝐨𝐦𝐢𝐧𝐠 𝐒𝐨𝐨𝐧: BiotechTV visited Monte Rosa Therapeutics, Inc in Boston today and spoke with Markus Warmuth about the latest in molecular glue degraders. Watch for the full episode later this afternoon.

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Monte Rosa Therapeutics, Inc's CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders. $GLUE Full video: biotechtv.com/post/monte-ros…

𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited Monte Rosa Therapeutics, Inc in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.

Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. nature.com/articles/d4157…

Today we announced our second collaboration with Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/4piSOyN

Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in Nature Communications: rdcu.be/eQKQk